Cagrilintide also shows an ability to reduce overall caloric intake and food cravings , particularly for high-fat or high-sugar foods
These often improve as the body adjusts
Among GLP-1 RA users in the final study sample, the proportion of semaglutide users increased from 5.1% in 2018 to 63% in 2023 ( Meanwhile, from 2018 to 2023, the proportion of diabetic GLP-1 RA users decreased from 89% to 66%, respectively, and those without a diagnosis of diabetes (groups 3 and 4) tripled their share from 11% to 34% ( Among group 3 (without diabetes and without obesity/overweight), there was a steady increase in off-label semaglutide (Ozempic) prescribing from 3.6% to 30%, and off-label semaglutide (Wegovy) increased to 38% drug share in 2023
However, its particularly challenging during the holidays
Based on available data and mechanism of action, retatrutide appears most relevant for: People with significant obesity (BMI 35+) who want maximum weight reduction and haven't achieved their goals on semaglutide or tirzepatide People with type 2 diabetes who need both glycemic control and meaningful weight loss People who have plateaued on existing GLP-1 therapy and are wondering if a more powerful triple agonist would move the needle People focused on metabolic longevity , where reducing adiposity, improving insulin sensitivity, and lowering chronic inflammation are all high-priority goals If you're someone chasing a 5-10 lb cosmetic goal, retatrutide is probably overkill
Some researchers keep a 5mg vial specifically for the first two weeks at 1mg (using just 20 units per dose), then switch to larger vials for the remainder of the protocol